DeepSeq.AI announced the completion of an investment from Illumina Ventures. As part of the investment transaction, Martin Moorhead, PhD, Chief AI Scientist at Illumina Ventures, will join the DeepSeq board.
Support comes from new and existing investors, including life science, technology, growth, and sovereign wealth investors; Financing closely follows announcements of Iambic’s clinical data for IAM1363 at the ESMO Congress and entry into a clinical collaboration with Jazz Pharmaceuticals.
The company’s transformer model interprets up to one billion DNA fragments in each blood sample, capturing molecular context at a scale hundreds of times greater than leading LLMs and demonstrating strong clinical validation. With $6.7 million seed led by Felicis Ventures and Illumina Ventures, Hepta advances liquid biopsy platforms beyond oncology.
Spotlight on Tom Willis, PhD – CEO Arima Genomics
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
